Why Sellas Life Sciences Group Inc. (SLS) Stock Rose 156.4% on Nov 17, 2026
as of Tuesday, 4:25 PM ET
The reason we found
SELLAS surges after leukemia vaccine succeeds in Phase 3 trial
SELLAS reported that its galinpepimut-S cancer vaccine met the primary endpoint in the Phase 3 REGAL trial, reducing the risk of death by 41% and extending median survival. The positive late-stage result materially improves the therapy’s commercial prospects, plausibly driving the stock’s 156.76% jump.
clinical trial resulthigh confidence
Sources 10
- SLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What’s Next for SELLAS Life Sciences? - Coinpedianews.google.com
- SLS Nov 2026 4.500 put (SLS261120P00004500) Stock Price, News, Quote & History - Yahoo! Finance Canadanews.google.com
- Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trialproactiveinvestors.com
- SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpointnasdaq.com
- Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trialnasdaq.com
- SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Shares - TradingViewnews.google.com
- Sellas Life Sciences: REGAL Hits, But The Data Leaves Too Many Questions Unansweredfinnhub.io
- SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpointfinnhub.io
- SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Sharesfinnhub.io
- SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Toofinnhub.io
Our call
Keepdated Nov 20, 2026
Sellas Life Sciences rose 74% over the past five trading days while other health care stocks fell 6.4%, and analysts expect profit to grow 54% next year. Sellas Life Sciences' next report could raise the call with a profit beat, or lower it with a miss.
Other moves on Nov 17
- SPCE−17.3%Virgin Galactic Slides After Analysts Cut Price Targets
- ACM+11.1%AECOM jumps on earnings beat and stronger 2027 outlook
- CRM−9.4%Salesforce Slides on Engineering Chief Departure and AI Fears
- MNSO+8.3%MINISO reports strong nine-month revenue growth despite Q3 misses
- ENPH−7.5%Evercore cuts Enphase price target to $30
- IONQ−7.0%IonQ slides after downgrade flags costly shareholder dilution